On March 22, 2013, IP Osgoode and the Canadian Intellectual Property Office (CIPO) co-hosted a conference examining the role of student researchers in commercializing intellectual property. Inspired by her SSHRC-funded research, IP Osgoode’s Professor Giuseppina D’Agostino, the conference chair, skillfully orchestrated an impressive line-up of guest speakers and panellists representing the full spectrum of key stakeholders who shared their unique perspectives on this important and timely issue.

Read the rest of this entry »

Posted in Canada, Feature Post, IP, Jurisdiction
Comments: 0

As part of Osgoode’s Intellectual Property Law Intensive Program, I had the opportunity to spend ten weeks at Teva Canada working with in-house counsel. Teva Canada is one of Canada’s largest generic pharmaceutical companies that also has a brand division focusing on the development of innovative products in several therapeutic areas.

Read the rest of this entry »

Posted in Canada, Feature Post, IP, IP Intensive, Patent Practice, Patents
Comments: 0

The Canadian pharmaceutical industry is entering a new era as Subsequent Entry Biologic (SEB) litigation begins to emerge in the Canadian pharmaceutical landscape. Biologic drugs are derived through the metabolic activity of living organisms and tend to be significantly more variable and structurally complex then chemically synthesized drugs.

Read the rest of this entry »

Posted in IP Intensive, Patent Practice, Patents, Pharmaceutical Drugs
Comment: 1

On November 8, 2012 the Supreme Court of Canada (SCC) released its eagerly anticipated decision in the “Viagra Appeal”. In a unanimous decision written by Justice LeBel, the SCC found the patent at issue invalid for insufficient disclosure. This decision marks the end of a lengthy legal battle between Teva and Pfizer over the validity of Canadian Patent 2,163,446 (the “446 Patent”).

Read the rest of this entry »

Posted in Access to Medicines, Canada, Feature Post, IP, Patents, Pharmaceutical Drugs
Comment: 1